Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (August 2024)
24 slides from Sona Nanotech's investor presentation, August 2024
Slide 1: Sona's THT Therapy: Solid Tumor Volume Reduction & Immune System Activation
Sona’s THT Therapy: Solid Tumor Volume Reduction & Immune System Activation A Novel, 1-2 Punch Against Cancer August 2024 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Who we are: Sona's Gold Nanorods
Who we are Sona’s Gold Nanorods (“GNRs”) o We make highly functional rod-shaped, gold nanoparticles ▪ Shape permits most efficient conversion of light to heat ▪ Aspect ratio enables them to be tuned to specific energy wavelengths to enable heating and potentially triggering of conjugated molecules ▪
Slide 4: What we do: Targeted Hyperthermia Therapy (THT)
What we do Targeted Hyperthermia Therapy (“THT”) Sona’s THT Cancer Therapy: 1. We inject gold nanorods into cancer tumors 2. We apply a near infrared light source 3. We heat the nanoparticles within a specific temperature range 4. This causes death of tumor cells This also causes neo-antigens to be
Slide 5: The Problem: Late Stage, Unresectable Melanoma, For Which Too Often Nothing Else Works
The Problem: Late Stage, Unresectable Melanoma, For Which Too Often Nothing Else Works Currently no alternative once NCCN recommended treatments fail Note 1. Initial algorithm for the management of locally advanced melanoma. AJCC indicates American Joint Committee on Cancer; IIIB, in-transit and/or
Slide 6: Dalhousie Preclinical Efficacy Study
What we have done so far Dalhousie Preclinical Efficacy Study Recent Preclinical Study Research Study Shows THT’s Strong Efficacy in Melanoma and Triple Negative Breast Cancer, With Pronounced Abscopal Effect Principal Investigator: Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) Professor, Faculty
Slide 7: Dalhousie Preclinical Efficacy Study – Key Questions
What we have done so far Dalhousie Preclinical Efficacy Study – Key Questions Efficacy study of the THT with melanoma and triple negative breast cancer • In each case, two cancer tumors were was implanted on either side of a mouse. • Only tumors on one side of the mouse were treated. • Natural tumor
Slide 8: Initial Treatment Results
What we have done so far Initial Treatment Results Results of initial treatment alone show: • one treatment reduced the primary tumor by an Tumor volume average of approximately 80% (4T1 Breast Cancer Model) • cancer tumors can grow back after the first treatment Tumor volume (%Day 0) C 600 G 400 Co
Slide 9: The Effects of Multiple THT Treatments
What we have done so far The Effects of Multiple THT Treatments Tumor Volume - B16 Enhanced Tumor Reduction with Two THT Treatments (B16 Melanoma Cancer Mouse Tumor Model, n=3) • The first treatment 600 reduces the primary Tumor Volume (mm3) tumor by approximately 80% 400 • Follow up Control THT sin
Slide 10: A Single THT Treatment Triggered A Systemic Immune Response
What we have done so far A Single THT Treatment Triggered A Systemic, Immune Response 4T1 – Breast Cancer B16 - Melanoma • Nanoparticle facilitated Ccl7 Ccl7 hypothermia inside tumor causes Cxcl10 Cxcl10 Cxcl9 Cxcl9 neo-antigen presentment, Relative Gene Expression (ΔΔCt) IFNa1 Relative Gene Express
Slide 11: THT Combined With IL-2
What we have done so far Tumor volume - B16 (Melanoma) THT Combined With IL-2 600 • IL-2 is a standard immunotherapeutic drug used to treat cancer. Control Tumor Volume (mm3) IL-2 • IL-2 and other checkpoint inhibitors can 400 THT have a significant positive effect on THT+IL-2 cancer patients when t
Slide 12: THT Showed A Vaccine-like Effect
What we have done so far THT Showed A Vaccine-like Effect Contralateral Tumor Volume - B16 (Melanoma) In mice with one tumor treated 400 with THT and IL-2, an abscopal Control effect was seen whereby Tumor volume (mm3) distant, untreated tumors 300 IL2 shrunk. THT (single treatment) Further, newly i
Slide 13: FDA-vetted Development Milestones for THT Safety Studies
What we need to do from here FDA-vetted Development Milestones for THT Safety Studies Based on the substantial success the company has achieved in its preclinical studies, Sona's near-term objectives will focus on four areas: • Complete final analysis, publish in 2024 2025 medical journal and peer r
Slide 14: Immunotherapy Drug Response Rates Are Low
Immunotherapy Drug Response Rates Are Low. What Could Be The Impact On Lives If THT Improved Response Rates By Even 10%? Immunotherapy Response Rate in Study of 1678 Patients by Cancer Type 100% 90% 80% 70% 60% 50% 40% 30% Average response rate of 21% 20% 10% 0% Note: Patients treated with anti–prog
Slide 15: Sona Has Engineered the Right Team to Develop Its THT Cancer Therapy
Sona Has Engineered the Right Team to Develop Its THT Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Chairman Director Director Director o Led vaccine maker Sanofi- o CSO of Khosla Ventures o Led Medtronic Canada for ~20 o 25 years of experience in Pasteur to a billion-
Slide 16: Investment Summary
Investment Summary • Unique, patented and vetted platform technology • Elegant and powerful therapy – simple and strong immune system activator • Compelling pre-clinical efficacy data in two cancer models (third pending) • FDA vetted plan for studies with credible, international partners to get to h
Slide 17: Capitalization Table
Capitalization Table Market Capitalization Ownership Share Price C$0.30 Board and Market Cap. C$30M 16% Management 52 Week High/Low $0.56/$0.135 Capital Structure Issued & Outstanding 99M Options 6.0M Public 84% Warrants 3.1M As of July 2, 2024 sonanano.com 17
Slide 18: Recent News
Recent News Sona nanotech: ss ¥ Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results Sona Nanotech Announces Filing of Provisional Patent Application MARCH 25, 2024 MARCH 18, 2024 \ TEMaprreueverererten ses COMPANY NEWS, NEWS RELEASES: Sona’s Cancer Therapy Creates Sona Appoints Chi
Slide 19: Thank you
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan david@sonanano.com CEO Sona Nanotech Inc. +1 902 448 1416 CSE: SONA | OTCQB: SNANF sonanano.com 19
Slide 20: Appendix
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Appendix sonanano.com 20
Slide 21: Hyperthermia Triggers Antigen Presentation To The Immune System
Hyperthermia Triggers Antigen Presentation To The Immune System Gold nanorods Adapted from Pharmaceutics 13(8):1147 21
Slide 22: Key Immune System Indicators
What we have done so far Key Immune System Indicators B16 Melanoma Model Study Data Dendritic cell count Macrophage count M1 count NK Cell count 2000 15000 5000 ✱ 20000 Cell count/10^6 cells Cell count/10^6 cells Cell count/10^6 cells Cell number/10^6 cells 4000 1500 10000 15000 3000 1000 10000 2000
Slide 23: THT + Immunotherapeutic Drug Potentiates an Immune Response
THT + Immunotherapeutic Drug Potentiates an Immune Response THT shrinks tumors and increases survival in animal models. Sona’s new preclinical studies now establish that: 1. THT stimulates the innate immune system • Priming it to help fight the cancer 2. THT upregulates gene expression of inflammato
Slide 24: Summary Of Dalhousie University Study Findings
Summary Of Dalhousie University Study Findings • GNR-induced hyperthermia triggers STING/innate immune response, reducing tumor volume drastically. • Combination with intratumoral IL-2 therapy leads to: • durable tumor reduction • more CD8+ infiltration • increased CD8+ memory subsets, and • higher